Otto-von-Guericke-Universität Magdeburg

Institut für Klinische Pharmakologie
 
 
 
 
 
 
 
 
 
 
 
 

C.V.

Prof. Dr. med. Dr. h. c. Stefanie M. Bode-Böger, MPH
e-mail: stefanie.bode-boeger@med.ovgu.de

Originalarbeiten

Reviews

CURRICULUM VITAE

1990 Medizinisches Staatsexamen, Medizinische Hochschule Hannover (MHH)
1990 Dr. med./MD, Institut für Klinische Pharmakologie, MHH (U. Förstermann)
1992 Approbation als Ärztin
1992 - 1993 Assistenzärztin in der Angiologie, Zentrum Innere Medizin, MHH (K. Alexander)
1993 - 1995 Institut für Klinische Pharmakologie, MHH (J.C. Frölich)
1995 - 1996 Ergänzungsstudiengang Bevölkerungsmedizin und Gesundheitswesen (Public Health) an der MHH
1996 - 1997 DFG fellow at Stanford University School of Medicine, Falk Cardiovascular Research Center (J.C. Cooke)
1997 Fachärztin für Klinische Pharmakologie
1998 Verleihung des Hochschulgrads "Magistra Sanitatis Publicae" (MPH)
1998 Venia legendi für das Fachgebiet "Klinische Pharmakologie", MHH
1998 Ernennung zur stellvertretenden Leiterin des Instituts für Klinische Pharmakologie, MHH
seit 2002 Direktorin des Instituts für Klinische Pharmakologie der Medizinischen Fakultät
der Otto-von-Guericke-Universität Magdeburg
2003 gewähltes Vorstandsmitglied der Deutschen Gesellschaft für Klinische Pharmakologie und Therapie e.V.
2009 Verleihung der Ehrendoktorwürde der Universität Pécs (Ungarn)

Pressemitteilung

Wissenschaftliche Auszeichnungen

April 1992 Young Investigator Award, Second International Symposium on Endothelium-Derived Vasoactive Factors, Basel
"Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin"
Mai 1992 Henry Christian Memorial Award, American Federation for Clinical Research
"Intravenous low dose aspirin selectively inhibits platelet aggregation and thromboxane synthesis in man"
Oktober 1992 Graduation Award, Medical School, Hannover, Germany
Oktober 1996 Rudolf-Schön-Award, Medical School, Hannover, Germany
"L-arginine induces NO-dependent vasodilation in patients with critical limb ischemia – a randomized, controlled study"
Oktober 1997 Jan-Brod-Award, Medical School, Hannover, Germany
"Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids"
November 1997 Samuel A. Levine Young Clinical Investigator Award, (Winner Finalists` Competition) American Heart Association
"Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction"
Juni 1998 ERA/EDTA-Award 1998, European Renal Association
"Elevation of an endogenous inhibitor of nitric oxide (NO) synthase inhibitor in end-stage renal disease (ESRD) – Influence of hemodialysis (HD) and CAPD"
April 1999 Paul-Martini-Award for Clinical Pharmacology, Paul-Martini-Foundation

Publikationen

Schuppner R, Dirks M, Grosse GM, Böckmann M, Goetz F, Pasedag T, Bode-Böger SM, Martens-Lobenhoffer J, Budde U, Lanfermann H, Lichtinghagen R, Weissenborn K, Worthmann H.
ADAMTS-13 activity predicts outcome in acute ischaemic stroke patients undergoing endovascular treatment.
Thromb Haemost 2018;118: 758-767.

Emrich IE, Zawada AM, Martens-Lobenhoffer J, Fliser D, Wagenpfeil S, Heine GH, Bode-Böger SM.
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Clin Res Cardiol 2018; 107: 201-213.

Worthmann H, Li N, Martens-Lobenhoffer J, Dirks M, Schuppner R, Lichtinghagen R, Kielstein JT, Raab P, Lanfermann H, Bode-Böger SM, Weissenborn K.
Dimethylarginines in patients with intracerebral hemorrhage: association with outcome, hematoma enlargement, and edema.
J Neuroinflammation 2017; 14: 247-255.

Rodionov RN, Heinrich A, Brilloff S, Jarzebska N, Martens-Lobenhoffer J, Bode-Böger SM, Todorov V, Hugo CP, Weiss N, Hohenstein B.
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Atherosclerosis Supplements 2017; 30: 319-325.

Martens-Lobenhoffer J, Bode-Böger SM.
Quantification of meropenem in human plasma by HILIC – tandem mass spectrometry.
J Chromatogr B 2017; 1046: 13-17.

Martens-Lobenhoffer J, Bode-Böger SM.
Separation of the structural isomers of monomethylarginine in human plasma by 2-D-HPLC and MS-MS detection.
Chromatographia 2017; 80: 45-51.

Bode-Böger SM.
Polypharmazie bei Dialysepatienten.
Dialyse aktuell 2016; 20 (Suppl. 1): S3.

Burdin DV, Kolobov AA, Brocker C, Soshnev AA, Samusik N, Demyanov AV, Brilloff S, Jarzebska N, Martens-Lobenhoffer J, Mieth M, Maas R, Bornstein SR, Bode-Böger SM, Gonzalez F, Weiss N, Rodionov RN.
D iabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanineglyoxylate aminotransferase 2.
Sci Rep 2016; 6: 35503-35515

Rodionov RN, Oppici E, Martens-Lobenhoffer J, Jarzebska N, Brilloff S, Burdin D, Demyanov A, Kolouschek A, Leiper J, Maas R, Cellini B, Weiss N, Bode-Böger SM.
A Novel Pathway for Metabolism of the Cardiovascular Risk Factor Homoarginine by alanine: glyoxylate aminotransferase 2.
Sci Rep 2016; 6: 35277-35288.

Schmidt JJ, Bode-Böger SM, Wilhelmi M, Omar M, Martens-Lobenhoffer J, Welte T, Kielstein JT.
Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing.
J Antimicrob Chemother 2016; 71: 2673-2674.

Schmidt JJ, Ramazan L, Bockemeyer C, Günter HH, Martens-Lobenhoffer J, Ganzenmüller T, Bode-Böger SM, Kielstein JT.
Acute interstitial nephritis due to flecainide therapy in the 38th week of pregnancy.
BMC Nephrology 2016, 17: 28.

Rodionov RN, Martens-Lobenhoffer J, Brilloff S, Burdin DV, Jarzebska N, Demyanov AV, Hohenstein B, Weiss N, Bode-Böger SM.
Acetylation of asymmetric and symmetric dimethylarginine: an undercharacterized pathway of metabolism of endogenous
methylarginines.
Nephrol Dial Transplant 2016; 31: 57-63.

Martens-Lobenhoffer J, Bode-Böger SM, Clement B. First detection and quantification of Ndelta-monomethylarginine, a structural isomer of NG-monomethylarginine, in humans using MS3. Analytical Biochemistry 2016; 493: 14-20.

Kielstein H, Suntharalingam M, Perthel R, Song R, Schneider SM, Martens-Lobenhoffer J, Jäger K, Bode-Böger SM, Kielstein JT. Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease. Nephrol Dial Transplant 2015; 30: 1699-1705.

 

Martens-Lobenhoffer J, Bode-Böger SM.
A validated method for the quantification of fosfomycin in human plasma by liquid chromatography-tandem mass spectrometry.
J Chromatogr B 2015; 990: 164-168.

Martens-Lobenhoffer J, Bode-Böger SM.
Amino acid N-acetylation: Metabolic elimination of symmetric dimethylarginine as symmetric Nα-acetyldimethylarginine, determined in human plasma and urine by LC-MS/MS.
J Chromatogr B 2015; 975: 59-64.

Rodionov RN, Martens-Lobenhoffer J, Brilloff S, Hohenstein B, Jarzebska N, Jabs N, Kittel A, Maas R, Weiss N, Bode-Böger SM.
Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy.
Nephrol Dial Transplant 2014; 29: 2035-2042.

Krajewski J, Bode-Böger SM, Tröger U, Martens-Lobenhoffer J, Mulrooney T, Mittelstädt H, Russlies M, Kirchner R, Knobloch JKM.
Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
Int J Antimicrob Agents 2014; 44: 363-366.

Strunk AK, Schmidt JJ, Baroke E, Bode-Böger SM, Martens-Lobenhoffer J, Welte T, Kielstein JT.
Single-and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis.
J Antimicrob Chemother. 2014; 69: 2008-2010.

Schepers E, Speer T, Bode-Böger SM, Fliser D, Kielstein JT.
Dimethylarginines ADMA and SDMA: The real water-soluble small toxins?
Semin Nephrol 2014; 34: 97-105.

Martens-Lobenhoffer J, Rodionov RN, Bode-Böger SM.
Determination of asymmetric N alpha-acetyldimethylarginine in humans: a phase II metabolite of asymmetric dimethylarginine.
Anal Biochem 2014; 452: 25-30.

Lukasz A, Hoffmeister B, Graf B, Wölk B, Noeckler K, Bode-Böger SM, Hadem J, Pischke S, Kielstein JT.
Association of angiopoietin-2 and dimethylarginines with complicated course in patients with leptospirosis.
PLoS ONE 2014; 9(1): e87490.

Martens-Lobenhoffer J, Surdacki A, Bode-Böger SM.
Fast and precise quantification of L-homoarginine in human plasma by HILIC-isotope dilution-MS-MS.
Chromatographia 2013; 76: 1755-1759.

Tutarel O, Röntgen P, Bode-Böger SM, Martens-Lobenhoffer J, Westhoff-Bleck M, Diller GP, Bauersachs J, Kielstein JT.
Symmetrical dimethylarginine is superior to NT-proBNP for detecting systemic ventricular dysfunction in adults after atrial repair for transposition of the great arteries.
Int J Cardiol 2013; 168: 4415-4416.

Jaźwińska-Kozuba A, Martens-Lobenhoffer J, Kruszelnicka O, Rycaj J, Chyrchel B, Surdacki A, Bode-Böger SM.
Opposite associations of plasma homoarginine and ornithine with arginine in healthy children and adolescents.
Int J Mol Sci 2013; 14: 21819-21832.

Bode-Böger SM, Schopp B, Tröger U, Martens-Lobenhoffer J, Kalousis K, Mailänder P.
Intravenous colistin in a patient with serious burns and borderline syndrome: The benefits of therapeutic drug monitoring.
Int J Antimicrob Agents 2013; 42: 357-360.

Tamás P, Bódis J, Sulyok E, Kovács GL, Hantosi E, Molnár G, Martens-Lobenhoffer J, Bode-Böger SM.
L-arginine metabolism in early-onset and late-onset pre-eclamptic pregnancies.
Scand J Clin Lab Invest 2013; 73: 436-43.

Worthmann H, Martens-Lobenhoffer J, Joumaah M, Li N, Lichtinghagen R, Hecker H, Kielstein JT, Ehrenreich H, Bode-Böger SM, Weissenborn K.
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke.
Stroke 2013; 44: 2128-2133.

Veldink H, Faulhaber-Walter R, Park JK, Martens-Lobenhoffer J, Bode-Böger SM, Schuett H, Haghikia A, Hilfiker-Kleiner D, Kielstein JT.
Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice.
Nephrol Dial Transplant 2013; 28: 1434-1439.

Beutel G, Perthel R, Suntharalingam M, Bode-Böger SM, Martens-Lobenhoffer J, Kielstein JT, Kielsteinn H.
Effect of chronic elevated asymmetric dimethylarginine (ADMA) levels on granulopoiesis.
Ann Hematol 2013; 92: 505-508.

Kittel A, Maas R, König J, Mieth M, Weiss N, Jarzebska N, Hohenstein B, Martens-Lobenhoffer J, Bode-Böger SM, Rodionov RN.
In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice.
Biochem Biophys Res Commun 2013; 430: 84-9.

Padberg JS, Meurs M, Kielstein JT, Martens-Lobenhoffer J, Bode-Böger SM, Zijlstra JG, Kovesdy CP, Kümpers P.
Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia.
Exp Transl Stroke Med 2012; 4: 24.

Chen S, Martens-Lobenhoffer J, Weissenborn K, Kielstein JT, Lichtinghagen R, Deb M, Li N, Tryc AB, Goldbecker A, Dong Q, Bode-Böger SM, Worthmann H.
Association of dimethylarginines and mediators of inflammation after acute ischemic stroke.
J Neuroinflammation 2012; 9: 251.

Martens-Lobenhoffer J, Rodionov RN, Bode-Böger SM.
Probing AGXT2 enzyme activity in mouse tissue by applying stable isotope-labeled asymmetric dimethyl arginine as substrate.
J Mass Spectrom 2012; 47: 1594-1600.

Jaźwińska-Kozuba A, Martens-Lobenhoffer J, Surdacki A, Kruszelnicka O, Rycaj J, Godula-Stuglik U, Bode-Böger SM.
Associations between Endogenous Dimethylarginines and Renal Function in Healthy Children and Adolescents.
Int J Mol Sci 2012; 13: 15464-15474.

Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M, Tribouilloy C, Choukroun G, Maziere JC, Bode-Böger SM, Kielsltein JT, Drüeke TB, Massy ZA.
Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.
Cardiovasc Res 2012; 96: 130-139.

Vida G, Sulyok E, Ertl T, Martens-Lobenhoffer J, Bode-Böger SM.
Birth by cesarean section is associated with elevated neonatal plasma levels of dimethylarginines.
Pediatrics International 2012; 54: 476-479.

Tröger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Böger SM.
Decreased meropenem levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
International Journal of Antimicrobial Agents 2012; 40: 370-372.

Martens-Lobenhoffer J, Bode-Böger SM.
Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry.
J Chromatogr B 2012; 904: 140-143.

Drust A, Luchtmann M, Firsching R, Tröger U, Martens-Lobenhoffer J, Bode-Böger SM.
Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function?
Epilepsy & Behavior 2012; 23: 394-395.

Kielstein JT, Suntharalingam M, Perthel R, Rong S, Martens-Lobenhoffer J, Jäger K, Bode-Böger SM, Nave H.
Asymmetric dimethylarginine may mediate increased heat pain threshold in experimental chronic kidney disease.
Nephrol Dial Transplant 2012; 27: 899-902.

Tutarel O, Denecke A, Bode-Böger SM, Martens-Lobenhoffer J, Lovric S, Bauersachs J, Schieffer B, Westhoff-Bleck M, Kielstein JT.
Asymmetrical dimethylarginine – more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease.
PLoS ONE 2012; 7: Issue 3, e33795, 1-6.

Götte A, Hammwöhner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D, Ravens U, Weinert S, Medunjanin S, Lendeckel U, Bode-Böger SM.
The impact of rapid atrial pacing on ADMA and endothelial NOS.
Int J Cardiol 2012; 154: 141-6.

Scherbakov N, Sandek A, Martens-Lobenhoffer J, Kung T, Turhan G, Liman T, Ebinger M, v. Haehling S, Bode-Böger SM, Endres M, Doehner W.
Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke.
Cerebrovasc Dis 2012; 33: 37-46.

Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Perthel R, Lovric S, Lichtinghagen R, Kliem V, Bode-Böger SM.
Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors.
Am J Physiol Renal Physiol 2011; 301: F1042–F1046.

Worthmann H, Chen S, Martens-Lobenhoffer J, Li N, Deb M, Tryc AB, Goldbecker A, Dong Q, Kielstein JT, Bode-Böger SM, Weissenborn K.
High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke.
J Atheroscler Thromb 2011; 18: 753-761.

Lehmann HI, Götte A, Martens-Lobenhoffer J, Hammwöhner M, Röhl F-W, Bukowska A, Ghanem A, Klein HU, Bode-Böger SM.
Asymmetric dimethylarginine predicts appropriate implantable cardioverter–defibrillator intervention in patients with left ventricular dysfunction.
Europace 2011; 13: 1428-1435.

Martens-Lobenhoffer J, Rodionov RN, Drust A, Bode-Böger SM.
Detection and quantification of a-keto-d-(NG,NG-dimethylguanidino)valeric acid: a metabolite of asymmetric dimethylarginine.
Analytical Biochemistry 2011; 419: 234-240.

Bugnicourt JM, da Silveira C, Bengrine A, Godefroy O, Baumbach GL, Sevestre H, Bode-Böger SM, Kielstein JT, Massy ZA, Chillon JM.
Chronic renal failure alters endothelial function in cerebral circulation in mice.
Am J Physiol Heart Circ Physiol 2011; 301: H1143-H1152.

Martens-Lobenhoffer J, Rupprecht V, Bode-Böger SM.
Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?
J Chrom B 2011; 879: 2051-2056.

Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Burg M, Lorenzen JM, Lichtinghagen R, Bode-Böger SM, Kliem V.
SDMA is an early marker of change in GFR after living-related kidney donation.
Nephrol Dial Transplant 2011; 26: 324-328.

Reiche I, Westphal S, Martens-Lobenhoffer J, Tröger U, Luley C, Bode-Böger SM.
Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Nephrol Dial Transplant 2011; 26: 276-282.

Tutarel O, Denecke A, Bode-Böger SM, Martens-Lobenhoffer J, Schieffer B, Westhoff-Bleck M, Kielstein JT.
Symmetrical Dimethylarginine Outperforms CKD-EPI and MDRD-Derived eGFR for the Assessment of Renal Function in Patients with Adult Congenital Heart Disease.
Kidney Blood Press Res 2011; 34: 41-45.

Bódis J, Várnagy Á, Sulyok E, Kovács GL, Martens-Lobenhoffer J, Bode-Böger SM.
Negative association of L-arginine methylation products with oocyte numbers.
Hum Reprod 2010; 25: 3095-3100.

v. Haehling S, Bode-Böger SM, Martens-Lobenhoffer J, Rauchhaus M, Schefold JC, Genth-Zotz S, Karhausen T, Cicoira M, Anker SD, Doehner W.
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol.
Clin Pharmacol Ther 2010; 88: 506-512.

Götte A, Wolfram O, Jentsch-Ullrich K, Martens-Lobenhoffer J, Scalera F, Lendeckel U, Bode-Böger SM.
The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA.
Int J Cardiol 2010; 143: 264-270.

Tröger U, Reiche I, Jepsen MS, Huth C, Bode-Böger SM.
Esomeprazole-induced rhabdomyolysis in a patient with heart failure.
Intensive Care Med 2010; 36: 1278-1279.

David S, Kümpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Böger SM, Kliem V, Haller H, Kielstein JT.
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
Nephrol Dial Transplant 2010; 25: 2571-2576.

Rifai K, Bode-Böger SM, Martens-Lobenhoffer J, Ernst T, Kretschmer U, Hafer C, Fliser D, Manns MP, Kielstein JT.
Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption.
Scand J Gastroenterol 2010; 45: 1110-1115.

Reiche I, Tröger U, Martens-Lobenhoffer J, Kandulski A, Neumann H, Malfertheiner P, Bode-Böger SM.
Omeprazole-induced cough in a patient with gastroesophageal reflux disease.
Eur J Gastroenterol Hepatol 2010; 22: 880-882.

Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Böger SM, Hiss M, Kielstein JT.
Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis.
J Antimicrob Chemother 2010; 65: 1312-1314.

Rifai K, Bode-Böger SM, Martens-Lobenhoffer J, Ernst T, Kretschmer U, Hafer C, Fliser D, Manns MP, Kielstein JT.
Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption.
Scand J Gastroenterol 2010; online 1-6

Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-Böger SM, Martens-Lobenhoffer J, Greer MW, Stass H, Welte T.
Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.
Intensive Care Med 2010; 36: 979-983.

Kielstein JT, Engbers C, Bode-Böger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmüller F, Knitsch W, Hafer C, Burkhardt O.
Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis – a pharmacokinetic study.
Nephrol Dial Transplant 2010; 25: 1537-1541.

Lorenzen J, Krämer R, Kliem V, Bode-Böger SM, Veldink H, Haller H, Fliser D, Kielstein JT.
Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease.
Eur J Clin Invest 2010; 40: 294-300.

Ajtay Z, Németh A, Sulyok E, Cziráki A, Szabados S, Martens-Lobenhoffer J, Awiszus F, Szabó C, Bode-Böger SM.
Effect of stent implementation on plasma levels of asymmetric dimethylarginine in patients with or without ST-segment elevation acute myocardial infarction.
Int J Mol Med 2010; 25: 617-624.

Henken S, Bohling J, Martens-Lobenhoffer J, Paton JC, Ogunniyi AD, Briles DE, Salisbury VC, Wedekind D, Bode-Böger SM, Welsh T, Bange FC, Welte T, Maus UA.
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmunary infections with streptococcus pneumoniae.
Antimicrob Agents Chemother 2010; 54: 707-717.

Martens-Lobenhoffer J, Dautz C, Bode-Böger SM.
Improved method for the determination of cyclic guanosine monophosphate (cGMP) in human plasma by LC-MS/MS.
J Chromatogr B 2010; 878: 487-491.

Scalera F, Fulge B, Martens-Lobenhoffer J, Heimburg A, Bode-Böger SM.
Red wine decreases asymmetric dimethylarginine via SIRT1 induction in human endothelial cells.
Biochem Biophys Res Comm 2009; 390: 703 – 709.

Kielstein J, Burkhardt O, Bode-Böger SM.
Dose matters: dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. (Letter to the Editor)
Crit Care Med 2009; 37: 2491.

Martens-Lobenhoffer J, Becker A, Freude H, Bode-Böger SM.
Identification and quantification of the atypical metabolite ornithine-lactam in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
J Chromatogr B 2009; 877: 2284-2289.

Scalera F, Closs EI, Flick E, Martens-Lobenhoffer J, Boissel JP, Lendeckel U, Heimburg A, Bode-Böger SM.
Paradoxical effect of L-arginine: acceleration of endothelial cell senescence.
BBRC 2009; 386: 650-655.

Reiche I, Tröger U, Postel SC, Wolf R, Bode-Böger SM.
Valproic acid-induced myopathy in a patient with schizoaffective disorder. (Letter to the Editor)
J Clin Psychopharmacol 2009; 29: 402-403.

Kielstein JT, Hesse, G, Bahr MJ, Tsikas D, Terkamp C, Martens-Lobenhoffer J, Manns MP, Haller H, Panning B, Bode-Böger SM, Gebel M.
Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection – role of ethanol, hemolysis, asymmetric dimethylarginine, and the nitric oxide system.
Crit Care Med 2009; 37: 1483-1485.

Ajtay Z, Scalera F, Cziráki A, Horváth I, Papp L, Sulyok E, Szabo C, Martens-Lobenhoffer J, Awiszus F, Bode-Böger SM.
Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA.
Int J Mol Med 2009; 23: 651-657.

Surdacki A, Martens-Lobenhoffer J, Wloch A, Gluszko P, Rakowski T, Dubiel JS, Bode-Böger SM.
Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration.
Metabolism Clinical and Experimental 2009; 58: 316-318.

Vida G, Sulyok E, Lakatos O, Ertl T, Martens-Lobenhoffer J, Bode-Böger SM.
Plasma levels of asymmetric dimethylarginine in premature neonates: its possible involvement in developmental programming of chronic diseases.
Acta Paediatrica 2009; 98: 437-441.

Gödecke VA, Clajus C, Burkhardt O, Martens-Lobenhoffer J, Bode-Böger SM, Kielstein JT, Hiss M.
Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient.
Scand J Infect Dis 2009; 41: 155-157.

Kielstein J, Martens-Lobenhoffer J, Vollmer S, Bode-Böger SM.
L-arginine, ADMA, SDMA, creatinine, MDRD formula: detour to renal function testing.
J Nephrol 2008; 21: 959-961.

Kielstein J, Burkhardt O, Bode-Böger SM.
Dose matters: dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. (Letter to the Editor)
Crit Care Med 2009; 37: 2491.

Surdacki A, Martens-Lobenhoffer J, Brzozowska-Czarnek A, Rakowski T, Galicka-Latala D, Wieczorek-Surdacka E, Mielecki W, Urbanik A, Dudek D, Dubiel JS, Bode-Böger SM.
Excessive epicaridial fat volume is not associated with elevated plasma asymmetrical dimethyl-L-arginine in optimally treated patients after myocardial infarction.
Kardiodiabetologia 2008; 3: Nr. 1 – 2, 1 – 4.

Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Täger M, Bode-Böger SM.
Effect of telmisartan on nitric oxide–asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Hypertension 2008; 51: 696-703.

Csiky B, Sulyok E, Lakatos O, Wittmann I, Martens-Lobenhoffer J, Bode-Böger SM.
Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients.
Nephron Clin Pract 2008; 108: c127-c134.

Martens-Lobenhoffer J, Reiche I, Tröger U, Mönkemüller K, Malfertheiner P, Bode-Böger SM.
Enantioselective quantification of omeprazole and its main metabolites in human serum by chiral HPLC–atmospheric pressure photoionization tandem mass spectrometry.
J Chromatogr B 2007; 857: 301-307.

Martens-Lobenhoffer J, Postel S, Tröger U, Bode-Böger SM.
Determination of ornithine in human plasma by hydrophilic interaction chromatography – tandem mass spectrometry.
J Chromatogr B 2007; 855: 271-275.

Martens-Lobenhoffer J, Bode-Böger SM.
Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids.
J Chromatogr B 2007; 851: 30-41.

Martens-Lobenhoffer J, Sulyok E, Czeiter E, Büki A, Kohl J, Firsching R, Tröger U, Bode-Böger SM.
Determination of cerebrospinal fluid concentrations of arginine and dimethylarginines in patients with subarachnoid haemorrhage.
J Neurosci Methods 2007; 164: 155-160.

Walter S, Kuchenbecker J, Banditt P, Bode-Böger SM, Behrens-Baumann W.
Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose.
JCRS 2007; 33: 553-555.

Vida G, Sulyok E, Ertl T, Martens-Lobenhoffer J, Bode-Böger SM.
Plasma asymmetric dimethylarginine concentration during the perinatal period.
Neonatology 2007; 92: 8-13.

Surdacki A, Martens-Lobenhoffer J, Wloch A, Marewicz E, Rakowski T, Wieczorek-Surdacka E, Dubiel JS, Pryjma J, Bode-Böger SM.
Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis.
Arthritis Rheum 2007; 56: 809-819.

Surdacki A, Stochmal E, Szurkowska M, Bode-Böger SM, Martens-Lobenhoffer J, Stochmal A, Klecha A, Kawecka-Jaszcz K, Dubiel JS, Huszno B, Szybinski Z.
Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance.
Metabolism 2007; 56: 77-86.

Wieczorek-Surdacka E, Surdacki A, Bode-Böger SM, Schubert B, Sulowicz W.
Elevated plasma asymmetric dimethyl-L-arginine in a patient with Gordon syndrome.
Nephrol Dial Transplant 2007; 22: 268-271.

Kielstein J, Donnerstag F, Gasper S, Menne J, Fliser D, Kielstein A, Martens-Lobenhoffer J, Scalera F, Bode-Böger SM, Cooke J.
Response to letter by Tsuda – Asymmetric dimethylarginine and cerebrovascular disorders in humans.
Stroke 2006; 37: 2871.

Kalousová M, Kielstein JT, Hodková M, Zima T, Dusilová-Sulková S, Martens-Lobenhoffer J, Bode-Böger SM.
No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients.
Blood Purif 2006; 24: 439-444.

Kielstein JT, Salpeter SR, Bode-Böger SM, Cooke JP, Fliser D.
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta-analysis.
Nephrol Dial Transplant 2006; 21: 2446-2451.

Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM.
ADMA increases arterial stiffness and decreases cerebral blood flow in humans.
Stroke 2006; 37: 2024-2029.

Götte A, Hammwöhner M, Dierkes J, Lachmuth J, Frölich JC, Klein H, Bode-Böger SM.
Aortic thrombus and pulmonary embolism in a patient with hyperhomocysteinemia.
Nat Clin Pract Cardiovasc Med 2006; 3: 396 – 399.

Scalera F, Martens-Lobenhoffer J, Täger M, Bukowska A, Lendeckel U, Bode-Böger SM.
Effect of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging.
Biochem Biophys Res Comm 2006; 345: 1075 – 1082.

Menne J, Park JK, Agrawal R, Lindschau C, Kielstein JT, Kirsch T, Marx A, Muller D, Bahlmann FH, Meier M, Bode-Böger SM, Haller H, Fliser D.
Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
FASEB J 2006; 20: E150 – E159.

Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H.
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
J Am Soc Nephrol 2006; 17: 1128-1134.

Westphal S, Taneva E, Kästner S, Martens-Lobenhoffer J, Bode-Böger S, Kropf S, Dierkes J, Luley C.
Endothelial dysfunction induced by postprandial lipemia is neutralized by addition of proteins to the fatty meal.
Atherosclerosis 2006, 185: 313-319.

Martens-Lobenhoffer J, Bode-Böger SM.
Fast and Efficient Determination of Arginine, Symmetric Dimethylarginine, and Asymmetric Dimethylarginine in Biological Fluids by Hydrophilic-Interaction Liquid Chromatography–Electrospray Tandem Mass Spectrometry.
Clinical Chemistry 2006; 52: 488-493.

Westphal S, Borucki K, Luley C, Martens-Lobenhoffer J, Bode-Böger SM.
Treatment with niacin lowers ADMA.
Atherosclerosis 2006; 184: 448-450.

Kielstein J, Czock D, Schöpcke T, Hafer C, Bode-Böger SM, Kuse E, Keller F, Fliser D.
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Crit Care Med 2006; 34: 51-56.

Martens-Lobenhoffer J, Westphal S, Awiszus F, Bode-Böger SM, Luley C.
Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA?
Clinical Chemistry 2005; 51: 2188-2189.

Tröger U, Lins H, Scherrmann JM, Wallesch CW, Bode-Böger SM.
Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier.
BMJ 2005; 331: 613.

Bode-Böger SM, Scalera F, Martens-Lobenhoffer J.
Asymmetric dimethylarginine (ADMA) accelerates cell senescence.
Vasc Med 2005; 10: S65-71.

Bode-Böger SM, Martens-Lobenhoffer J, Täger M, Schröder H, Scalera F.
Aspirin reduces endothelial cell senescence.
Biochem Biophys Res Comm 2005; 334: 1226-1232.

Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E.
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
J Am Soc Nephrol 2005; 16: 2456-2461.

Kielstein J, Bode-Böger SM (equally contributed), Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM.
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.
Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418.

Martens-Lobenhoffer J, Bode-Böger SM.
Determination of levetiracetam in human plasma with minimal sample pretreatment.
J Chromatogr B 2005; 819: 197-200.

Scalera F, Kielstein J, Martens-Lobenhoffer J, Postel S, Täger M, Bode-Böger SM.
Erythropoietin increases asymmetric dimethylarginine in endothelial cells – role of dimethylarginine dimethylaminohydrolase.
J Am Soc Nephrol 2005; 16: 892-898.

Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Täger M, Bode-Böger SM.
Endogenous NO-synthesis inhibitor asymmetric dimethyl L-arginine (ADMA) accelerates endothelial cell senescence.
Arterioscler Thromb Vasc Biol 2004; 24: 1816-1822.

Martens-Lobenhoffer J, Krug O, Bode-Böger SM.
Determination of arginine and asymmetric dimethylöarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique.
J Mass Spectrom 2004; 39: 1287-1294.

Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D.
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
Circulation 2004; 109: 172-177.

Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D.
Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition.
Kidney Blood Press Res 2004; 27: 143-147.

Kielstein JT, Böger RH, Bode-Böger SM, Martens-Lobenhoffer J, Lonnemann G, Frölich JC, Haller H, Fliser D.
Low dialysance of asymmetric dimethylarginine (ADMA) – in vivo and in vitro evidence of significant protein binding.
Clinical Nephrology 2004; 62: 295-300.

Sydow K, Hornig B, Arakawa N, Bode-Böger SM,Tsikas D, Münzel T, Böger RH.
Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Vasc Med 2004; 9: 93-101.

Böger RH, Tsikas D, Bode-Böger SM, Phivthong-ngam L, Schwedhelm E, Frölich JC.
Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-15N2]-arginine to 15N-labeled nitrate by gas chromatography-mass spectrometry.
Nitric Oxide 2004; 11: 1-8, online.

Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Böger SM.
Fenofibrate increases the L-arginine: ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
Atherosclerosis 2004; 173: 239-244.

Martens-Lobenhoffer J, Bode-Böger SM.
Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation.
J Chromatogr B 2003; 798: 231-239.
Top Cited Article Award 2001 - 2006.

Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC.
Oral L-arginine improves endothelial function in healthy individuals older than 70 years.
Vasc Med 2003, 8: 77-81.

Kielstein JT, Bode-Böger SM, Haller H, Fliser D.
Functional changes in the ageing kidney: is there a role for asymmetric dimethylarginine?
Nephrol Dial Transplant 2003; 18: 1245-1248.

Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D.
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects.
Circulation 2003, 107: 1891-1895.

Kielstein JT, Bode-Böger SM, Graf S, Haller H, Fliser D.
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure.
Eur J Clin Invest 2003, 33: 370-375.

Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, Frölich JC, Böger RH.
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
Cardiovasc Res 2003; 57: 244-252.

Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, Fliser D.
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
J Am Soc Nephrol 2002; 13: 170-176.

Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Catalotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH.
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
Lancet 2001; 358: 2113-2117.

Walker HA, McGing E, Fisher I, Böger RH, Bode-Böger SM, Jackson G, Ritter JM, Chowienczyk PJ.
Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance.
J Am Coll Cardiol 2001; 38: 499-505.

Böger RH, Lentz SR, Bode-Böger SM, Knapp HR. Haynes WG.
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.
Clin Sci 2001; 100: 161-167.

Kielstein JT, Bode-Böger SM, Frölich JC, Haller H, Böger RH.
Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
Kidney Int 2001; 59 (Suppl. 78): 9-13.

Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP.
An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.
J Am Coll Cardiol 2000; 36: 2287-95.

Brandes RP, Brandes S, Böger RH, Bode-Böger SM, Mügge A.
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix.
Life Sci 2000; 66:1519-24.

Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH.
Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use.
Int J Clin Pharmacol Ther 2000; 38: 504-513.

Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM.
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases.
Circ Res 2000; 87: 99-105.

Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Frölich JC.
Hypothesis: Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox.
FEBS Lett 2000; 478: 1-3.

Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR.
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Arterioscler Thromb Vasc Biol 2000; 20: 1557-1564.

Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP.
Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans.
Arterioscler Thromb Vasc Biol 2000; 20: 1040-1046.

Bode-Böger SM, Böger RH, Kielstein JT, Löffler M, Schäffer J, Frölich JC.
Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis.
J Investig Med 2000; 48: 125-132.

Osterziel KJ, Bode-Böger SM, Strohm O, Ellmer AE, Bit-Avragim N, Hänlein D, Ranke MB, Dietz R, Böger RH.
Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy.
Cardiovasc Res 2000; 45: 447-453.

Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, Krusnelnicka-Kwiatkowska O, Kokot F, Dubiel J, Frölich JC.
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.
J Cardiovasc Pharmacol 1999; 33: 652-658.

Bode-Böger SM, Böger RH, Löffler M, Tsikas D, Brabant G, Frölich JC.
L-arginine stimulates NO-dependent vasodilation in healthy humans-effect of somatostatin pretreatment.
J Invest Med 1999; 47: 43-50.

Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC.
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
J Am Soc Nephrol 1999; 10: 594-600.

Brandes RP, Behra A, Lebherz C, Böger RH, Bode-Böger SM, Mügge A.
Lovastatin maintains nitric oxide- but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery.
Atherosclerosis 1999; 142: 97-104.

Bode-Böger SM, Böger RH, Schubert M, Gutzki FM, Tsikas D, Frölich JC.
Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Eur J Clin Pharmacol 1998; 54: 707-714.

Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
J Am Coll Cardiol 1998; 32: 1336-1344.

Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
J Am Coll Cardiol 1998; 32: 1336-1344.

Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP.
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Circulation 1998; 98: 1842-1847.

Bode-Böger SM, Böger RH, Galland A, Tsikas D, Frölich JC.
L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharamcodynamic relationship.
Br J Clin Pharmacol 1998; 46: 489-497.

Phivthong-ngam L, Böger RH, Bode-Böger SM, Böhme M, Mügge A, Frölich JC.
Effect of lovastatin on plaque formation and LDL oxidation in cholesterol-fed rabbits.
Thai J Pharmacol 1998; 20: 11-22.

Böger RH, Bode-Böger SM, Phivthong-ngam L, Brandes RP, Schwedhelm E, Mügge A, Böhme M, Tsikas D, Frölich JC.
Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms.
Atherosclerosis 1998; 141: 31-43.

Phivthong-ngam L., Bode-Böger SM, Böger RH, Böhme M, Brandes RP, Mügge A, Frölich JC.
Dietary L-arginine normalizes endothelin-induced vascular contractions in cholesterol-fed rabbits.
J Cardiovasc Pharmacol 1998; 32: 300-307.

Bode-Böger SM, Böger RH, Kienke S, Böhme M, Phivthong-ngam L, Tsikas D, Frölich JC.
Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolemic rabbits in vivo.
Cardiovasc Res1998; 37: 756-764.

Bode-Böger SM, Böger RH, Galland A, Frölich JC.
Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Naunyn-Schmiedeberg`s Arch Pharmacol 1998; 357: 143-150.

Böger RH, Bode-Böger SM, Kienke S, Stan AC, Nafe R, Frölich JC.
Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits.
Atherosclerosis 1998; 136: 67-77.

Brandes RP, Behra A, Lebherz C, Böger RH, Bode-Böger SM, Phivthong-Ngam L, Mügge A.
NG-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia.
Atherosclerosis 1997; 135: 49-55.

Schellong SM, Böger RH, Burchert W, Bode-Böger SM, Galland A, Frölich JC, Hundeshagen H, Alexander K.
Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease - a H215O-positron emission tomography study.
Clin Sci 1997; 93: 159-165.

Böger RH, Bode-Böger SM, Böhme M, Phivthong-ngam L, Brandes RP, Nafe R, Mügge A, Frölich JC.
Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits – comparison with lovastatin.
Circulation 1997; 96: 1282-1290.

Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC.
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
Circulation 1997; 95: 2068-2074.

Böger RH, Skamira C, Bode-Böger SM, Brabant G, von zur Mühlen A, Frölich JC.
Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.
J Clin Invest 1996; 98: 2706-2713.

Böger RH, Bode-Böger SM, Kramme P, Tsikas D, Gutzki FM, Frölich JC.
Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low-dose acetylsalicylic acid.
Br J Clin Pharmacol 1996; 42: 721-727.

Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frölich JC.
Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids.
Kidney Int 1996; 50: 1255-1261.

Böger RH, Mügge A, Bode-Böger SM, Heinzel D, Höper M, Frölich JC.
Differential systemic and pulmonary haemodynamic effects of L-arginine in patients with coronary heart disease or primary pulmonary hypertension.
Int J Clin Pharmacol Ther 1996; 34: 323-328.

Mügge A, Kurucay S, Böger RH, Bode-Böger SM, Schäfers HJ, Wahlers T, Frölich JC, Lichtlen PR.
Urinary nitrate excretion is increased in cardiac transplanted patients with acute graft rejection.
Clin Transplant 1996; 10: 298-305.

Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC.
Elevated L-arginine / dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.
Biochem Biophys Res Commun 1996; 219: 598-603.

Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, Alexander K, Frölich JC.
L-arginine induces nitirc oxide-dependent vasodilation in patients with critical limb ischemia – a randomized, controlled study.
Circulation 1996; 93: 85-90.

Böger RH, Bode-Böger SM, Gerecke U, Gutzki FM, Tsikas D, Frölich JC.
Urinary nitrate excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats.
Clin Exp Pharmacol Physiol 1996; 23: 11-15.

Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC.
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production.
Atherosclerosis 1995; 117: 273-284.

Böger RH, Bode-Böger SM, Frölich JC.
Consensus conferences – impact on clinical prescribing habits.
Int J Clin Pharm Ther 1995; 33: 471-472.

Tsikas D, Böger RH, Bode-Böger SM, Brunner G, Frölich JC.
Formation of S-nitroso compounds from sodium nitroprusside, nitric oxide or nitrite and reduced thiols: analysis by capillary isotachophoresis.
J Chromatogr A 1995; 699: 363-369.

Böger RH, Bode-Böger SM, Schröder P, Tsikas D, Frölich JC.
Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin.
J Appl Physiol 1995; 78: 1832-1838.

Böger RH, Bode-Böger SM, Kuhn M, Otten A, Frölich JC.
Interaction of superoxide anions with activation of soluble guanylyl cyclase by glyceryl trinitrate, linsidomine, and sodium nitroprusside.
Pharm Pharmacol Lett 1995; 5: 10-13.

Tsikas D, Böger RH, Bode-Böger SM, Gutzki FM, Frölich JC.
Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography - mass spectrometry using their 15N-labelled analogs.
J Chromatography B 1994; 661: 185-191.

Mügge A, Brandes R, Böger RH, Dwenger A, Bode-Böger SM, Kienke S, Frölich JC, Lichtlen PR.
Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits.
J Cardiovasc Pharmacol 1994; 24: 994-998.

Tsikas D, Stichtenoth DO, Böger RH, Bode-Böger SM, Frölich JC.
Synthesis of nitric oxide releasing, vasodilating and platelet aggregation inhibiting S-[15N]-nitroso compounds.
J Lab Comp Radiopharmac 1994; 34: 1055-1062.

Stichtenoth DO, Gutzki FM, Tsikas D, Selve N, Bode-Böger SM, Böger RH, Frölich JC.
Increased urinary nitrate excretion in rats with adjuvant arthritis.
Ann Rheum Dis 1994; 53: 547-549.

Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K, Frölich JC.
L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects.
Clin Sci 1994; 87: 303-310.

Bode-Böger SM, Böger RH, Schröder EP, Frölich JC.
Exercise increases systemic nitric oxide production in men.
J Cardiovasc Risk 1994; 1: 173-178.

Böger RH, Bode-Böger SM, Gerecke U, Frölich JC.
Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats.
Cardiovasc Res 1994; 28: 494-499.

Ranke C, Creutzig A, Luska G, Wagner H-H, Galanski M, Bode-Böger SM, Frölich JC, Avenarius H-J, Hecker H, Alexander K.
Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease.
Clin Investig 1994; 72: 673-680.

Ranke C, Creutzig A, Luska G, Wagner H-H, Galanski M, Bode-Böger SM, Frölich JC, Avenarius H-J, Hecker H, Alexander K.
Dosisabhängige Nebenwirkungen der Acetylsalicylsäuretherapie: Ergebnisse einer prospektiven, randomisierten klinischen Studie bei Patienten mit peripherer arterieller Verschlußkrankheit.
Med Klinik 1993; 88 (10): 571-576.

Böger RH, Bode-Böger SM, Gutzki FM, Tsikas D, Weskott HP, Frölich JC.
Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man.
Clin Sci 1993; 84: 517-524.

Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frölich JC.
Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin.
J Cardiovasc Pharmacol 1992; 20 (Suppl. 12): S25-S28.

Bode SM, Kuhn M, Förstermann U.
Chemotactic peptide FMLP contracts human coronary arteries via cyclooxygenase products.
Am J Physiol 1990; 258: H848-H853.

Mügge A, Bode SM, Wahlers T, Haverich A, Lichtlen PR, Frölich JC, Förstermann U.
Aggregierende menschliche Thrombozyten stimulieren die Produktion des endothelialen relaxierenden Faktors (EDRF) in menschlichen Koronararterien.
Cor Vas 1989; 1/2: 7-11.

Förstermann U, Mügge A, Alheid U, Bode SM, Frölich JC.
Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries.
Eur Heart J 1989; 10 (Suppl. F): 36-43.

Förstermann U, Mügge A, Bode SM, Frölich JC.
Response of human coronary arteries to aggregating platelets: importance of endothelium-derived relaxing factor and prostanoids.
Circ Res 1988; 63: 306-312.

Bode-Böger SM, Tröger U.
Therapeutisches Drug Monitoring (TDM) bei Intensivpatienten mit mulitresistenter Keimbesiedlung.
In: Kluge S, Markewitz A, Jorch G, Putensen C. Quintel M, Sybrecht GW (Hrsg.). DIVI Jahrbuch 2015/2016, Fortbildung und Wissenschaft in der interdisziplinären Intensivmedizin und Notfallmedizin, Schwerpunkt “Hygiene in der Intensivmedizin". Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2016, S. 29-37.

Bode-Böger SM, Tröger U.
Therapeutisches Drug Monitoring von Reserveantibiotika.
Intensivmed.up2date 2015; 11: 293-308.

Bode-Böger SM.
Optimierung der Antiinfektivatherapie mittels therapeutischen Drug-Monitorings.
Der Nephrologe 2014; 9: 457-464.

Martens-Lobenhoffer J, Bode-Böger SM.
Mass spectrometric quantification of L-arginine and its pathway related substances in biofluids: the road to maturity.
J Chromatogr B 2014; 964: 89-102.

Scalera F, Bode-Böger SM.
Asymmetric dimethylarginine accelerates cellular senescence.
In: Hayat MA (Hrsg.). Tumor Dormancy, Quiescence, and Senescence, Volume 2: Aging, Cancer, and Noncancer Pathologies. Springer Science+Business Media Dordrecht 2014, S. 3-16.

Bukowska A, Lendeckel U, Bode-Böger SM, Götte A.
Physiologic and pathopyhsiologic role of calpain: implications for the occurrence of atrial fibrillation.
Cardiovasc Ther 2012; 30: e115 – e127.

Scalera F, Bode-Böger SM.
Nitric oxide – asymmetric dimethylarginine system in endothelial cell senescence.
In: Ignarro L (Hrsg.). Nitric Oxide: Biology and Pathobiology. 2. Edition. Elsevier Academic Press Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney Tokio, 2010, S. 483-511.

Bode-Böger SM, Scalera F, Ignarro L.J.
The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio.
Pharmacol Ther 2007; 114: 295-306.

Tröger U, Bode-Böger SM.
Stellenwert von Neuraminidase-Hemmern in der Prophylaxe und Therapie der Influenza.
Dtsch Ärztebl 2006; 103: A 3486-3492.

Bode-Böger SM.
L-Arginin – präventive Wirkung bei Arteriosklerose?
Perfusion 2006; 19: 92-98.
Journal Pharmakol u Ther 2006; 5: 155-162.

Bode-Böger SM.
Effect of L-arginine supplementation on NO production in man.
Eur J Clin Pharmacol 2006; 62: 91-99.

Martens-Lobenhoffer J, Bode-Böger SM.
Measurement of asymmetric dimethylarginine (ADMA) in human plasma: from liquid chromatography estimation to liquid chromatography-mass spectrometry quantification.
Eur J Clin Pharmacol 2006; 62: 61-68.

Bode-Böger SM, Kojda G.
Organic nitrates in cardiovascular disease.
Cell Mol Biol 2005; 51:307-320.

Postel SC, Bode-Böger SM.
Erfassung von Aspekten der Arzneimittelsicherheit in der Apotheke – Fakt oder Fiktion?
Apothekenmagazin 2005; 23 (4): 72-78.

Bode-Böger SM.
Einfluss von L-Arginin auf die Arterioskleroseentwicklung: Was ist therapeutisch gesichert?
Dtsch Med Wochenschr 2005; 130: 593-598.

Fliser D, Kielstein JT, Haller H, Bode-Böger SM.
Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease?
Kidney Int. 2003; 63 (Suppl. 84): 37-40.

Böger RH, Bode-Böger SM.
The clinical pharmacology of L-arginine.
Annu Rev Pharmacol Toxicol 2001; 41: 79-99.

Böger RH, Bode-Böger SM.
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Semin Thromb Haemost 2000; 26: 539-45.

Bode-Böger SM.
Von der Idee zur Therapie: die kardiovaskulären Effekte von L-Arginin.
Med Welt 1999; 50: 91-96.

Bode-Böger SM.
Von der Idee zur Therapie: die klinische Pharmakologie von L-Arginin.
Klin Pharmakol akt 1998; 9 (2): 77-81.

Böger RH, Bode-Böger SM.
Endothelial dysfunction in peripheral arterial disease – from basic science to clinical application.
VASA 1997; 26: 180-184.

Bode-Böger SM, Böger RH, Frölich JC.
Antiarteriosklerotische Wirkungen durch Stimulation der endogenen NO-Synthese.
Internist 1997; 38: 461-465.

Böger RH, Bode-Böger SM, Frölich JC.
Pathogenetische Bedeutung des L-Arginin – NO-Stoffwechselwegs bei Arteriosklerose und mögliche therapeutische Aspekte.
VASA 1996; 25: 305-316.

Böger RH, Bode-Böger SM, Frölich JC.
The L-arginine – nitric oxide pathway: role in atherosclerosis and therapeutic implications.
Atherosclerosis 1996; 127: 1-11.

Böger RH, Bode-Böger SM, Alfke H.
Restenose nach perkutaner transluminaler Angioplastie. II. Möglichkeiten der pharmakologischen Intervention.
VASA 1996; 25: 21-31.

Alfke H, Böger RH, Bode-Böger SM.
Restenose nach perkutaner transluminaler Angioplastie. I. Ätiologie und klinische Bedeutung.
VASA 1996; 25: 13-20.

Bode-Böger SM, Böger RH, Frölich JC.
Rationale und kosteneffektive Volumenersatztherapie mit Humanalbumin und künstlichen Kolloiden.
Apotheken-Magazin 1995; 13: 230-235.

Böger RH, Bode-Böger SM, Frölich JC.
Intravenöse Immunglobuline – Grundlagen, Auswahlkriterien und Indikationen für ihren prophylaktischen und therapeutischen Einsatz.
Med. Klinik1995; 90: 520-526.

Böger RH, Bode-Böger SM.
Die klinische Pharmakologie von Stickstoffmomoxid (NO). Teil 2.
Apotheken-Magazin 1994; 12 (7): 166-170.

Böger RH, Bode-Böger SM.
Die klinische Pharmakologie von Stickstoffmomoxid (NO). Teil 1.
Apotheken-Magazin 1994; 12 (6): 134-136.

Böger RH, Bode-Böger SM, Frölich JC.
Volumenersatztherapie mit Humanalbumin – Grundlagen, Differentialindikationen und Alternativen.
Med Klinik 1993; 88: 371-376.

Bode-Böger SM, Böger RH, Frölich JC.
Therapeutisches Drug Monitoring in der Praxis – Indikation und Interpretation.
Z Ärztl Fortbild 1993; 87: 201-210.

Letzte Änderung: 09.08.2018 - Ansprechpartner: Webmaster
 
 
 
 
Kontakt

Direktorin
Prof. Dr. med. Dr. h. c.
Stefanie M. Bode-Böger
Fachärztin für Klinische Pharmakologie
C.V.

Hausanschrift
Otto-von-Guericke-Universität

Medizinische Fakultät
Leipziger Straße 44
D-39120 Magdeburg

Standort
Haus 1, Ebene 4
Lageplan

Sekretariat
Tel.: 03 91/ 67-13060
Fax: 03 91/ 67-13062
e-mail senden

Konsiliardienst / TDM
Dr. med. U. Tröger
Tel.: 03 91/ 67-13065

Fax: 03 91/ 67-13070

TDM Labor
Tel.: 03 91/ 67-13063
Fax: 03 91/ 67-13070